Glaxo seeks buyers for older products worth up to $12.6B

Carly Helfand GlaxoSmithKline has already made some moves to sell off some of its older meds. But now, it's making more that could end up much, much bigger. FiercePharma News

Retrophin soars on its latest rare disease play

Damian Garde Retrophin, the biotech helmed by hedge funder Martin Shkreli, leapt more than 25% after buying the rights to another drug with the potential to treat a rare disease. FierceBiotech ...

Amgen’s Vectibix scores first-line approval in wild-KRAS colorectal cancer

John Carroll The FDA has OK'd the use of Amgen's Vectibix as a first-line treatment for wild-type KRAS metastatic colorectal cancer. The agency approved the frontline use of ...

Teva keeps the faith after another rebuke for Copaxone’s heir

Damian Garde Teva's $ 4-billion-a-year multiple sclerosis treatment Copaxone is slated to lose patent protection next year, and the Israeli drugmaker is struggling to move the ...

Agile pulls off a $55M IPO after taking a 50% haircut

Damian Garde Princeton, NJ's Agile Therapeutics finally made its way onto Wall Street, pulling in $ 55 million after halving its expected share price. FierceBiotech News

Teva and Active Biotech not giving up on EU-spurned MS treatment

Carly Helfand The EU's Committee for Medicinal Products for Human Use (CHMP) is sticking to its opinion to recommend against approval of Teva and Active Biotech's MS drug Nerventra. ...

Isis surges on promising head-to-head thrombosis drug study

John Carroll Shares of Isis Pharmaceuticals surged 9% this morning as the Carlsbad, CA-based antisense drug developer posted positive outcomes for a head-to-head Phase II study comparing ...

Pharmstandard nabs Russia’s Biocad, with a little oligarch aid

Carly Helfand Last year, multinational drugmakers had their eyes on Russian biosimilars developer Biocad. But now, it's the country's own lead pharma company that will grab ...

Kindred to scale back animal research

Justin Heifetz The company will reformulate drugs already approved for humans and market them for pets, and expects FDA approval for three drugs for dogs by the end of the year. FiercePharma ...

UPDATED: Pfizer hikes bid for AstraZeneca to $117B, swears off hostile maneuver

John Carroll Pfizer has upped its bid for AstraZeneca to £55 a share, or $ 117 billion, hitting the "magic number" that bankers close to these talks ...

Forest CEO Saunders to lead combined company after Actavis buyout

Alok Saboo FierceBiotech News

Xinhua: Multinationals, beware–or end up like Glaxo

Carly Helfand "Ethics matter" in China–and it's time for multinationals to take note, according to the country's official news agency. With a reputation-tarnishing ...
Page 1 of 41234
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS